TAS-102 with or without celecoxib for leftover colon cancer DNA
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests TAS-102, with or without celecoxib, to treat “minimal residual disease” (tiny traces of colon cancer) found in a blood test after standard chemotherapy. The goal is to reduce the chance that colon cancer returns after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colorectal (colon or rectal) cancer on pathology.
- You had curative-intent surgery with no visible remaining tumor (R0) and finished all planned treatment, including at least 3 months of oxaliplatin chemotherapy.
- A recent scan shows no visible cancer, and your ctDNA blood test is positive for minimal residual disease (MRD).
- Your blood counts and organ function are strong enough (including neutrophils and platelets above required minimums).
- You can take pills by mouth, are not pregnant or breastfeeding, and can use reliable contraception during the study and for 7 months after the last dose.
- You must be 18 or older and be able to sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called AMB-05X for people with colorectal cancer who have completed all intended treatments and show no signs of cancer on scans, but still have cancer DNA (ctDNA) in their blood. The goal is to see if AMB-05X can eliminate this remaining cancer DNA and prevent the cancer from coming back.
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.